QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

LXEO

QT70Lexeo Therapeutics, Inc. Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
4.93
-0.05-1.00%
OverviewShort InterestFilings
LXEOQT70Lexeo Therapeutics, Inc. Common Stock·NASDAQ
OverviewShort InterestFilings
4.93-1.00%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own8.83%
Shs Outstand78.52M
Perf Week17.38%
Market Cap391.04MForward P/E-EPS next Y-1.28Insider Trans-0.09%Shs Float-Perf Month10.04%
Enterprise Value326.63MPEG-EPS next Q-Inst Own-Short Float-Perf Quarter-14.85%
Income-84620566.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-49.33%
Sales-P/B1.75EPS next Y-9.04%ROA-34.95%Short Interest-Perf YTD-50.35%
Book/sh2.94P/C-EPS next 5Y-ROE-47.48%52W High10.99 -55.14%Perf Year25.77%
Cash/sh0.92P/FCF-EPS past 3/5Y-ROIC-40.94%52W Low3.60 36.94%Perf 3Y-
Dividend Est.-EV/EBITDA-3.83Sales past 3/5Y-Gross Margin0.00%Volatility7.11% 5.14%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)0.39Perf 10Y-
Dividend Ex-Date-Quick Ratio14.16Sales Y/Y TTM-Profit Margin0.00%RSI (14)50.91Recom1.80
Dividend Gr. 3/5Y-Current Ratio14.16EPS Q/Q-SMA204.65%Beta1.99Target Price10.00
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA50-9.27%Rel Volume1.93Prev Close4.98
Employees75LT Debt/Eq0.02Earnings-SMA200-31.01%Avg Volume766.72KPrice4.93
IPO DateNov 03, 2023Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA0.76Volume1,481,272Change-1.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jan-13-26ReiteratedH.C. Wainwright$13 → $10
Dec-17-25InitiatedRaymond JamesStrong Buy$25
Dec-10-25ReiteratedOppenheimer$20
Nov-20-25InitiatedCantor FitzgeraldOverweight$19
Oct-21-25ReiteratedH.C. Wainwright$15 → $13
Oct-15-25InitiatedGuggenheimBuy$30
Oct-07-25ReiteratedH.C. Wainwright$9.00 → $15
Oct-07-25ReiteratedChardan CapitalBuy$17
Oct-07-25ReiteratedLeerink PartnersOutperform$20
Jun-12-24InitiatedBairdOutperform$28
Latest News
Jun-17-26
Jun-17-2604:04PM
Lexeo Therapeutics Reports Data For LX2006 Gene Therapy In Friedreich Ataxia, Pivotal SUNRISE-FA 2 Study On Track For 2026 Launch, Publishid In The JAMA CardiologyBenzinga
Jun-15-26
Jun-15-2603:52PM
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call TranscriptSeekingAlpha
01:01PM
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call - SlideshowSeekingAlpha
11:32AM
Why Is Lexeo Therapeutics Stock Gaining Monday?Benzinga
07:04AM
Lexeo Therapeutics Finalized SUNRISE-FA Pivotal Trial Protocol And Statistical Analysis Plan Intended To Provide Clinical Evidence To Support Submission FDA Application For Gene Therapy Candidate LX2006 Under The Accelerated Approval Pathway In 2028Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit000
Selling, General and Administrative Excl. Other453215
Research and Development647453
Other Operating Expense001
Operating Income-109-106-69
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-10-8-2
Net Income Before Taxes-100-98-66
Income Taxes
000
Consolidated Net Income-100-98-66
Net Income From Continuing Operations-100-98-66
Net Income-100-98-66
EPS (Recurring)-1.86-3.09-2.49
EPS (Basic, Before Extraordinaries)-1.86-3.09-2.49
EPS (Diluted)-1.86-3.09-2.49
EBITDA-98-96-64
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin———
Operating Margin———
Net Margin———
Shares Outstanding543227
Market Capitalization536——
Operating Lease Expense
———
Insider Trading Volume
$5.41$4.94$4.47$4.00$3.53● Close Price0.00K78.28K156.57K234.85K313.14KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Townsend Richard NolanChief Executive OfficerMay 18 '26Sale5.063,34216,927336,764May 20 12:00 AM
Otero Jose ManuelChief Operating OfficerMay 18 '26Sale5.071,3026,606130,088May 20 12:00 AM
Townsend Richard NolanChief Executive OfficerApr 06 '26Sale5.6955,000313,137340,106Apr 07 12:00 AM
Townsend Richard NolanChief Executive OfficerFeb 18 '26Sale6.3810,17364,924392,483Feb 20 12:00 AM
Otero Jose ManuelChief Operating OfficerFeb 18 '26Sale6.403,01619,294125,460Feb 20 12:00 AM
Otero Jose ManuelChief Operating OfficerNov 18 '25Sale9.277216,68463,476Feb 20 12:00 AM
Townsend Richard NolanChief Executive OfficerNov 18 '25Sale9.271,12710,447240,991Nov 20 12:00 AM
Adler EricChief Medical OfficerNov 18 '25Sale9.276155,70172,646Nov 20 12:00 AM
See Tai SandiChief Development OfficerNov 18 '25Sale9.273863,57865,476Nov 20 12:00 AM
Robertson JennyChief Legal OfficerNov 18 '25Sale9.275495,08968,381Nov 20 12:00 AM
Otero Jose ManuelChief Technical OfficerAug 18 '25Sale5.603,56919,97860,372Nov 20 12:00 AM
Robertson JennyChief Legal OfficerOct 17 '25Sale8.943,52631,52968,930Oct 17 12:00 AM
See Tai SandiChief Development OfficerOct 17 '25Sale8.943,88834,76765,862Oct 17 12:00 AM
Otero Jose ManuelChief Technical OfficerOct 17 '25Sale8.942,11518,91264,197Oct 17 12:00 AM
Adler EricChief Medical OfficerOct 17 '25Sale8.943,38230,24273,261Oct 17 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR